---
title: "CSPC Pharma says China clears clinical trial for RSV vaccine candidate SYS 6057"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294492639.md"
description: "CSPC Pharmaceutical received clearance from Chinese regulators to initiate clinical trials for its RSV vaccine candidate, SYS 6057. The trial aims to prevent RSV-related lower respiratory tract disease in adults aged 60 and older. The vaccine utilizes a pre-fusion F protein antigen combined with CSPC's proprietary second-generation nano-adjuvant platform."
datetime: "2026-07-31T09:56:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294492639.md)
  - [en](https://longbridge.com/en/news/294492639.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294492639.md)
generator: "portal-rs"
---

# CSPC Pharma says China clears clinical trial for RSV vaccine candidate SYS 6057

-   CSPC Pharmaceutical received Chinese regulator clearance to start clinical trials of its recombinant RSV vaccine candidate SYS 6057. \* The trial targets adults aged 60 and older to prevent RSV-related lower respiratory tract disease. \* The candidate uses a pre-fusion F protein antigen with CSPC’s in-house second-generation nano-adjuvant platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12264302), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [G Sachs Raises CSPC PHARMA  TP to HKD12.56, Highlights mRNA Vaccines](https://longbridge.com/en/news/296588621.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**